Study supports findings on Ocata treatment
A new study has affirmed encouraging results for treating macular degeneration using Ocata Therapeutics’ stem-cell line RPE, the Marlborough company reported.
The company, formerly Advanced Cell Technology, said treatment with the fully differentiated cells — RPE is short for retinal pigment epithelium —had positive results in Asian patients in a South Korean study.
The new research, Ocata said, supports earlier findings reported in in October.
The Korean study has been published online in Stem Cell Reports. It features 12 months of post-transplant follow-up data from four Asian patients; two with Stargardt’s macular degeneration (SMD) and two with dry age-related macular degeneration (AMD).
Paul K. Wotton, Octata’s president and CEO, said in the statement: “The safe treatment of a total of 42 patients across multiple studies with this novel therapeutic approach in geographically distinct patient populations is encouraging. We look forward to the planned initiation of our comprehensive Phase 2 safety study in dry AMD and a pivotal study in SMD, two disabling diseases where there is no cure available today.”
WBJ Web Partners
Most Recent
Most Recent
0 Comments